Evidence map›Paper›PMID 40719796›Full record

ArticleFunctional & integrative genomics2025

Integrated multi-omics analysis and machine learning refine molecular subtypes and prognosis in hepatocellular carcinoma through O-linked glycosylation genes.

Minghao Li, Hongxu Li, Lei Liu, Qianyi Wei, Jie Gao, Bowen Hu, Zhihui Wang, Wenzhi Guo, Yi Zhang, Shuijun Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minghao Li *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hongxu Li *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lei Liu *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qianyi Wei *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jie GaoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Bowen HuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhihui WangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenzhi GuoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yi ZhangDepartment of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. zhangyi@zzu.edu.cn.
Shuijun ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. zhangshuijun@zzu.edu.cn.

Funding

Medical Science and Technology Program of Henan SB201901045National Natural Science Foundation of China 81971881
6 · The paper itself

Abstract

O-glycosylation significantly influences cellular physiological processes and disease regulation by modulating the structure, function, and stability of proteins. However, there is a notable gap in research focusing on O-glycosylation in relation to the prognosis of HCC patients. The study aimed to explore the expression and function of O-glycosylation genes in HCC from both bulk- and single-cell perspectives. Multi-omics data related to O-glycosylation identified by weighted gene co-expression network analysis (WGCNA). This was then combined with ten different clustering algorithms to construct molecular subtypes of high-resolution HCC. Cancer subtype 1 (CS1) is characterized by significant genomic variation, moderate immune cell infiltration, and immune function enrichment. Patients with CS2 have a better prognosis and are characterized by a stable genomic structure, an immune-hot phenotype with rich immune cell infiltration, and sensitivity to immunotherapy. CS3 is characterized by poor prognosis, outstanding genomic instability, and an immune-cold phenotype, but can benefit more from treatment with drugs such as sorafenib, cisplatin, paclitaxel, and gemcitabine. To further emphasize the role of O-glycosylation genes in individual HCC patients, we employed 59 machine-learning methods to construct and assess prognostic traits with improved generalizability. Microarray results indicated a pronounced upregulation of glycosylation hub genes involved in HCC stratification and modeling within HCC tumorous tissues. Altogether, our study highlights the importance of O-glycosylation for the assessment of HCC prognosis and treatment options by redefining HCC subtypes and constructing a consensus machine learning-driven prognostic signature (CMLS). This research establishes an optimized decision-making platform that enables the precise stratification of HCC patients, refines tumor treatment plans, and predicts patient survivability, with broad clinical implications.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsMachine LearningGene Expression Regulation, NeoplasticGene Regulatory NetworksGlycosylationHumansMultiomicsPrognosisBiomarkers, TumorHepatocellular carcinomaMachine learningMulti-omicsO-Glycosylation modificationSubtype

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.